From LNP stability to outsourced manufacturing capacity, there’s no shortage of challenges to developing and manufacturing both viral and RNA-based therapeutic vaccines. In this segment of the Bioprocess Online Live event, guest experts Peter Berglund, chief scientific officer at HDT Bio, Johanna Kaufmann, EVP for oncology at Codagenix, and Robert Georgantas, president and CTO at Providence Therapeutics address those challenges, and our audience’s questions about them.
Check out the full webinar available on-demand - [ Ссылка ]
